Varicella-Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine

BackgroundA double-blind, placebo-controlled trial that involved 38,546 subjects ⩾60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific immune respon...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Levin, M. J, Oxman, M. N, Zhang, J. H, Johnson, G. R, Stanley, H, Hayward, A. R, Caulfield, M. J, Irwin, M. R, Smith, J. G, Clair, J, Chan, I. S. F, Williams, H, Harbecke, R, Marchese, R, Straus, S. E, Gershon, A, Weinberg, A
Formato: Artigo
Idioma:Inglês
Publicado: The University of Chicago Press 2008
Assuntos:
Major Articles And Brief Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4014857/
https://ncbi.nlm.nih.gov/pubmed/18419349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/528696
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares